These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 31426119)

  • 1. Minimal impact of hepatic and renal impairment on plasma protein binding of lenvatinib, and identification of its major plasma binding protein.
    Mano Y; Mizuo H
    Biopharm Drug Dispos; 2019 Sep; 40(8):307-311. PubMed ID: 31426119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration.
    Shumaker R; Aluri J; Fan J; Martinez G; Pentikis H; Ren M
    J Clin Pharmacol; 2015 Mar; 55(3):317-27. PubMed ID: 25204557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
    Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
    J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure.
    Zini R; Morin D; Salvadori C; Tillement JP
    Br J Clin Pharmacol; 1990 Jan; 29(1):9-18. PubMed ID: 2297464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of lenvatinib trough plasma concentrations with lenvatinib-induced toxicities in Japanese patients with thyroid cancer.
    Nagahama M; Ozeki T; Suzuki A; Sugino K; Niioka T; Ito K; Miura M
    Med Oncol; 2019 Mar; 36(5):39. PubMed ID: 30919115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A validated LC-MS/MS method of total and unbound lenvatinib quantification in human serum for protein binding studies by equilibrium dialysis.
    Mano Y; Kusano K
    J Pharm Biomed Anal; 2015 Oct; 114():82-7. PubMed ID: 26026266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.
    Motzer RJ; Hutson TE; Glen H; Michaelson MD; Molina A; Eisen T; Jassem J; Zolnierek J; Maroto JP; Mellado B; Melichar B; Tomasek J; Kremer A; Kim HJ; Wood K; Dutcus C; Larkin J
    Lancet Oncol; 2015 Nov; 16(15):1473-1482. PubMed ID: 26482279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer.
    Gupta A; Jarzab B; Capdevila J; Shumaker R; Hussein Z
    Br J Clin Pharmacol; 2016 Jun; 81(6):1124-33. PubMed ID: 26879594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis.
    Vanstraelen K; Wauters J; De Loor H; Vercammen I; Annaert P; Lagrou K; Spriet I
    J Pharm Sci; 2014 Aug; 103(8):2565-70. PubMed ID: 24961809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
    Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
    Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.
    Glen H
    Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.
    Hussein Z; Mizuo H; Hayato S; Namiki M; Shumaker R
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):903-914. PubMed ID: 28236116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.
    Shumaker R; Aluri J; Fan J; Martinez G; Ren M; Chen K
    Int J Clin Pharmacol Ther; 2014 Apr; 52(4):284-91. PubMed ID: 24548978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study.
    Matsubara N; Naito Y; Nakano K; Fujiwara Y; Ikezawa H; Yusa W; Namiki M; Okude T; Takahashi S
    Int J Urol; 2018 Nov; 25(11):922-928. PubMed ID: 30129060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contribution of plasma proteins, albumin and alpha 1-acid glycoprotein, to pharmacokinetics of a multi-targeted receptor tyrosine kinase inhibitor, sunitinib, in analbuminemic rats.
    Toyama Y; Ueyama J; Nomura H; Tsukiyama I; Saito H; Hisada T; Matsuura K; Hasegawa T
    Anticancer Res; 2014 May; 34(5):2283-9. PubMed ID: 24778032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of serum protein binding of felodipine.
    Valle M; Esteban M; Rodríguez-Sasiaín JM; Calvo R; Aguirre C
    Res Commun Mol Pathol Pharmacol; 1996 Oct; 94(1):73-88. PubMed ID: 8948016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
    De Lisi D; De Giorgi U; Lolli C; Schepisi G; Conteduca V; Menna C; Tonini G; Santini D; Farolfi A
    Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):461-467. PubMed ID: 29557694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor.
    Kiriyama A; Nishiura T; Ishino M; Yamamoto Y; Ogita I; Kiso Y; Takada K
    Biopharm Drug Dispos; 1996 Dec; 17(9):739-51. PubMed ID: 8968527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.
    Dubbelman AC; Nijenhuis CM; Jansen RS; Rosing H; Mizuo H; Kawaguchi S; Critchley D; Shumaker R; Schellens JH; Beijnen JH
    Invest New Drugs; 2016 Jun; 34(3):300-18. PubMed ID: 27018262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation.
    Li GF; Yu G; Li Y; Zheng Y; Zheng QS; Derendorf H
    J Pharm Sci; 2018 Jul; 107(7):1948-1956. PubMed ID: 29518400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.